AA
SION

AlphaCentric Advisors’s Sionna Therapeutics SION Stock Holding History

AlphaCentric Advisors’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193K Buy
4,818
+2,098
+77% +$80.1K 0.19% 148
2025
Q4 		$112K Buy
+2,720
New +$103K 0.11% 214

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AlphaCentric Advisors's SION Position: Q1 2026 in Review

AlphaCentric Advisors increased its Sionna Therapeutics (SION) stake by 77% in Q1 2026, buying an estimated $80.1K and bringing the position to 4,818 shares worth $193K. The position accounts for 0.19% of the portfolio, ranked #148.

AlphaCentric Advisors first reported a position in SION in Q4 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • AlphaCentric Advisors held 4,818 shares of Sionna Therapeutics worth $193K as of Q1 2026.
  • AlphaCentric Advisors bought 2,098 Sionna Therapeutics shares in Q1 2026, an estimated $80.1K.
  • Sionna Therapeutics made up 0.19% of AlphaCentric Advisors's portfolio in Q1 2026, its #148 holding.
  • AlphaCentric Advisors first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.